Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

This study is looking at how well new Alzheimer's medications (anti-amyloid antibodies) work in real-world Medicare patients with early-stage Alzheimer's disease. **You may be eligible if...** - You are a Medicare patient - You have been diagnosed with mild memory problems (mild cognitive impairment) or mild Alzheimer's dementia - A test has confirmed the presence of amyloid plaques in your brain, a hallmark of Alzheimer's disease **You may NOT be eligible if...** - No specific exclusion criteria have been listed for this study Talk to your doctor to see if this trial is right for you.